Document is current
Any future updates will be listed below
-
Authors
Rocha, Paula
Barroso, Julia
Carlos, Fernanda
Muxfeldt, Elizabeth
Gadelha, Monica
Kasuki, Leandro https://orcid.org/0000-0003-1339-3192
- License Information
-
More Information
Article History
Accepted: 14 April 2023
First Online: 29 May 2023
Declarations
:
: M.R.G. has served as an advisory board member for Ipsen, Novartis Pharmaceuticals, Novo Nordisk, Re-cordati Rare Diseases and Crinetics Pharmaceuticals; as a research investigator for Crinetics Pharmaceuticals, Recordati Rare Diseases and Novartis Pharmaceuticals; and as a speaker for Crinetics Pharmaceuticals, Novartis Pharmaceuticals, Ipsen, Novo Nordisk and Recordati Rare Diseases. L.K. has received speaker fees from Novartis and Ipsen.
: This study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of HUCFF/UFRJ (3. 858. 071) and Faculdade de Medicina da UFRJ and all patients signed written informed consent forms.
